Xeolas Facility Launch marks a significant development for Ireland’s pharmaceutical sector, as the Irish-owned specialty medicines company officially opens a 158,000-square-foot site in Baldoyle, Dublin. The new centre is designed to expand the company’s ability to research, develop and manufacture patient-friendly medicines for Irish and international markets.
The opening, announced on 16 September 2026, brings Xeolas’ pharmaceutical research, product development, manufacturing and regulatory functions together under one roof. The Baldoyle location also provides room for future expansion as demand increases for treatments aimed at patients whose needs are not fully addressed by conventional medicines.
Xeolas Facility Launch strengthens Ireland’s life sciences sector
Founded in Ireland in 2007 by pharmacist and pharmaceutical executive Damien Flynn, Xeolas now employs more than 100 people. The company specialises in reformulating established medicines to make them more accessible and suitable for specific patient groups, while drawing on existing clinical evidence.
Xeolas has a presence in 21 countries and is developing a pipeline of more than 25 products, several of which are at an advanced stage. Its work covers the full pharmaceutical value chain, including formulation, clinical development, regulatory submissions, manufacturing and commercial supply.
Existing products include Pedippi®, an oral omeprazole formulation developed for children, and Bonasol®, a drinkable alendronic acid solution. Products created by the company have received approval in major European markets and are sold internationally through commercial partners.
A platform for global growth
Xeolas founder and chief executive Damien Flynn described the new site as an important milestone for the business. He said the facility would give the company’s scientific, clinical, regulatory and commercial teams greater capacity to move medicines from development to commercial supply.
The company’s model focuses on improving established active substances rather than beginning every medicine from the earliest stage of discovery. This can support more targeted development and help create practical treatment options for patients with unmet needs.
Enterprise Ireland welcomes investment in advanced manufacturing
Leo McAdams, Head of Advanced Manufacturing, Construction and Lifesciences at Enterprise Ireland, congratulated Xeolas on the opening. He said supporting Irish companies with ambitions to scale internationally remains a key priority for the organisation.
The investment reinforces Ireland’s reputation as a centre for pharmaceutical innovation, advanced manufacturing and highly skilled employment. It also highlights the contribution of Irish-owned companies to the country’s export economy and life sciences ecosystem.
What the Xeolas development means for Ireland
The Baldoyle facility gives Xeolas an expanded base for scaling its medicines pipeline and serving global partners. It also supports broader national priorities around pharmaceutical manufacturing, research capability and high-value employment.
- Research, development and manufacturing operations are consolidated in Dublin.
- The facility is intended to support future growth and international supply.
- Xeolas continues to focus on patient-friendly formulations.
- The company contributes to Ireland’s specialist life sciences workforce.
Explore more
Frequently asked questions
What is the Xeolas Facility Launch?
It is the official opening of Xeolas Pharmaceuticals’ new 158,000-square-foot pharmaceutical facility in Baldoyle, Dublin.
What does Xeolas produce?
Xeolas develops patient-friendly formulations of established medicines, including products for children and treatments addressing specific patient needs.
How many people does Xeolas employ?
The company employs more than 100 people in Ireland.
Where does Xeolas operate?
Xeolas is present in 21 countries, with products marketed through partners across Europe and internationally.
Key takeaway: The Xeolas Facility Launch strengthens Ireland’s position in pharmaceutical innovation while giving an Irish-owned company the capacity to expand its medicines pipeline and international reach.
Article/Image Courtesy: Enterprise Ireland
